Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Canceled)

2. (Currently Amended) ~~Medicament according to~~ The method of claim ~~1, characterized in that~~ 16 wherein:

R^1 is selected from the group consisting of hydrogen, ~~an~~ substituted or unsubstituted alkyl, ~~an~~ substituted or unsubstituted alkenyl, and ~~or an~~ substituted or unsubstituted alkynyl, ~~it being possible for each of these groups to be~~ wherein when R^1 is substituted alkyl, substituted alkenyl, or substituted alkynyl, the substituent(s) thereof is (are) selected from the group consisting of ~~with an~~ alkoxy, [[a]] haloalkoxy, [[an]] alkylthiol, [[a]] halogen, ~~or a~~ unsubstituted phenyl, and phenyl ~~unsubstituted or~~ substituted with ~~an~~ a moiety selected from the group consisting of alkyl, ~~with a~~ haloalkyl, ~~with an~~ alkoxy, ~~with a~~ haloalkoxy, ~~with an~~ alkylthiol, and ~~or with a~~ halogen~~, or hydrogen~~;

R^2 and R^3 ~~which may be identical or different and which have the same definition as that given above for~~ are independently selected from the group consisting of R^1, ~~or which correspond to an~~ alkoxy, ~~an~~ alkoxyalkyl, a benzyloxy, a cyano, and ~~or an~~ alkylcarbonyl;

R^4 is ~~an~~ selected from the group consisting of:

(a) substituted or unsubstituted alkyl, ~~an~~ substituted or unsubstituted alkenyl, and ~~or an~~ substituted or unsubstituted alkynyl, ~~it being possible for each of these groups to be~~ wherein when R^4 is substituted alkyl, substituted alkenyl, or substituted alkynyl, the substituent(s) thereof is (are) selected from the group consisting of ~~with~~ an alkoxy, [[a]] haloalkoxy, [[an]] alkylthiol, a halogen, unsubstituted ~~or a~~ phenyl, and phenyl ~~unsubstituted or~~ substituted with ~~an~~ a moiety selected from the group consisting of alkyl, ~~with a~~ haloalkyl, ~~with an~~ alkoxy, ~~with a~~ haloalkoxy, ~~with an~~ alkylthiol, and ~~or with a~~ halogen;

(b) a hydroxyl;

(c) a halogen;

(d) a cyano;

(e) ~~an~~ acyl, ~~an~~ amine, [[a]] monoalkylamine, a dialkylamine, unsubstituted ~~or a~~ phenyl, and phenyl ~~unsubstituted or~~ substituted with a moiety selected from the group consisting of ~~an~~ alkyl, ~~with a~~ haloalkyl, ~~with an~~ alkoxy, ~~with a~~ haloalkoxy, ~~or with an~~ and alkylthiol;

m = 0 or 1;

when it is present, R^5 is a group having the same definition as that given above for R^4,

A is a direct bond, -O-, -S-, $-NR^9-$, $-CHR^7-$ or $-O-CHR^7-$,

~~with~~ each R^9, when ~~it is~~ any are present, ~~corresponding to an~~ is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, ~~an~~ substituted or unsubstituted alkenyl, and substituted or unsubstituted ~~or an~~ alkynyl, ~~it being possible for each of these groups to be~~ wherein when an R^9 is a substituted alkyl, a substituted alkenyl, or a substituted alkynyl, the

substituent(s) thereof is (are) selected from the group consisting of ~~with an~~ alkoxy, [[a]] haloalkoxy, ~~an~~ alkylthiol, [[a]] halogen, unsubstituted ~~or a~~ phenyl, and phenyl ~~unsubstituted or~~ substituted with ~~an~~ a moiety selected from the group consisting of alkyl, ~~with a~~ haloalkyl, ~~with an~~ alkoxy, ~~with a~~ haloalkoxy, ~~with an~~ alkylthiol, and ~~or with a~~ halogen~~, or corresponds to hydrogen~~;

~~and~~ R^7 ~~has the same definition as that given above for~~ is selected from the group consisting of R^9; ~~or represents a~~ hydroxyl; [[a]] halogen; [[a]] cyano; [[an]] acyl; alkoxy; [[a]] haloalkoxy; and ~~or an~~ alkylthiol;

A is linked to the 4-position of the benzene ring M; and

R^6 is a substituted or unsubstituted phenyl or an aromatic heterocycle~~, unsubstituted or substituted with one or more substituents, which may be identical or different, and which may be~~ which when R^6 is a substituted phenyl or substituted aromatic heterocycle, the substituent(s) thereof is (are) selected from the ~~following list:~~ group consisting of

(a) hydroxyl;

(b) halogen;

(c) cyano;

(d) acyl;

(e) amine;

(f) alkylamine;

(g) dialkylamine;

(h) alkyl[[,]];

(i) haloalkyl[[,]];

(j) R^aO-alkyl[[,]];

(k) acyloxyalkyl[[,]];

(l) cyanooxyalkyl[[,]];

(m) alkoxy;

(n) haloalkoxy;

(o) alkylthiol;

(p) cycloalkyl unsubstituted or substituted with ~~an~~ a moiety selected from the group consisting of alkyl, [[a]] haloalkyl, ~~an~~ alkoxy, [[a]] haloalkoxy, and ~~or with an~~ alkylthiol; and

(q) benzyl unsubstituted or substituted with ~~an~~ a moiety selected from the group consisting of alkyl, [[a]] haloalkyl, ~~an~~ alkoxy, [[a]] haloalkoxy, and ~~or with an~~ alkylthiol.

3. (Currently Amended) ~~Medicament according to~~ The method of claim ~~1, characterized in that~~ 16 wherein:

$R^1 = H$

~~$R^2 = C_1$-C_6 alkyl preferably ethyl;~~

~~$R^3 = C_1$-C_6 alkyl, preferably methyl;~~

~~$R^4 = C_1$-C_6 alkyl, preferably methyl;~~

~~R^5=C_1-C_6 alkyl, preferably methyl~~ wherein R^2, R^3, R^4, and R^5 are independently selected from the group consisting of C_1-C_6 alkyl and R^5 is linked to the carbon at C_5 of the benzyl ring M, with m=1;

A is linked to the carbon at C_4 of the benzyl ring M and represents -O-; and

~~R^6=aryl, preferably benzyl, advantageously~~ R^6 is unsubstituted aryl or aryl substituted with at least one moiety selected from the group consisting of alkyl ~~and/or with at least one~~ and halogen.

4. (Currently Amended) ~~Medicament according to~~ The method of claim 3~~, characterized in that~~ wherein compound (I) is[[:]] selected from the group consisting of

N-ethyl-N-methyl-N'-[4-(4-chloro-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide,

~~and/or~~ N-ethyl-N-methyl-N'-[4-(4-fluoro-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide,

~~and/or~~ N-ethyl-N-methyl-N'-[4-(4-cyano-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide,

and the possible tautomers and salts~~, in particular addition salts with an acid or a base, which~~ that are pharmaceutically acceptable[[,]] of these compounds (I).

5. (Currently Amended) ~~Medicament according to~~ The method of claim ~~1, characterized in that it additionally comprises~~ 16 wherein the medicament further comprises at least one other antifungal compound (II).

6. (Currently Amended) ~~Medicament according to~~ The method of claim 5~~, characterized in that~~ wherein the antifungal compound (II) is ~~chosen from the following antifungal families:~~ selected from the group consisting of azoles~~, such as bifonazole, butoconazole, clotrimazole, eberconazole, econazole, fenticonazole, fluconazole, itraconazole, ketoconazole, miconazole, oxiconazole, posaconazole, sulconazole, terconazole, tioconazole, voriconazole, zinoconazole~~; polyenes~~, such as amphotericin B, nystatin~~; allylamines and benzylamines~~, such as butenafine, naftifine, terbinafine~~; thiocarbamates~~, such as tolnaftate~~; candins~~, such as caspofungin, cilofungin~~; nucleoside analogues~~, such as flucytosine~~; sordarins; polyoxines and nikkomycins~~, such as nikkomycins Z, J, pseudo J, PX, RZ, pseudo Z~~; pradimicins~~, such as pradimicin A~~; benanomycins; aureobasidins; UK-2A or UK-3A; and cationic peptides;
taken alone or as a mixture, and their possible tautomers and salts~~, in particular addition salts with an acid or a base,~~ and their lipid or liposomal formulations~~, which~~ that are pharmaceutically acceptable.

7. (Currently Amended) ~~Antifungal~~ The method ~~medicament according to~~ of claim ~~4,~~ ~~characterized in that~~ 5 wherein the mass ratio (I/II) is ~~defined as follows:~~ $0.02 \leq I/II \leq 50$ ~~preferably $0.1 \leq I/II \leq 20$ and still more preferably $0.5 \leq I/II \leq 10$~~.

8. (Currently Amended) ~~Antifungal~~ The method ~~medicament according to~~ of claim ~~4,~~ ~~characterized in that~~ 5 wherein the compound (I)/compound (II) ratio is chosen so as to produce a synergistic effect.

9. (Currently Amended) ~~Antifungal~~ The method ~~medicament according to~~ of claim 8~~,~~ ~~characterized in that~~ wherein the compound (I)/compound (II) ratio is between 0.5 and 10.

10. (Currently Amended) ~~Antifungal~~ The method ~~medicament according to~~ of claim ~~1,~~ ~~characterized in that it additionally comprises~~ 16 wherein the medicament further comprises at least one pharmaceutically acceptable excipient.

11. (Currently Amended) ~~Antifungal~~ The method ~~medicament according to~~ of claim ~~1,~~ ~~characterized in that it comprises~~ 5 wherein the medicament comprises from 0.5 to 99% of the combination of compound (I) and compound (II).

12 - 13 (Canceled)

14. (Currently Amended) ~~Use of an antifungal medicament according to~~ The method of claim ~~1~~, 16 wherein the infection is an ~~for the treatment of~~ *Candida albicans* ~~infections~~ infection.

15. (Currently Amended) ~~Use of an antifungal medicament according to~~ The method of claim ~~1~~, 16 wherein the infection is an ~~for the treatment of~~ *Aspergillus fumigatus* ~~infections~~ infection.

16. (New) A method for treating *Candida albicans* or *Aspergillus fumigatus* infections in humans or animals comprising administering to a patient in need of such treatment a pharmaceutically effective dose of an antifungal medicament comprising at least one compound of formula (I):



(I)

wherein:

R^1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, and a substituted or unsubstituted carbocyclic or heterocyclic monovalent group;

R^2 and R^3 are independently selected from the group consisting of R^1; a cyano; an acyl; $-OR^a$ or $-SR^a$, wherein R^a is selected from the group consisting of a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, and a substituted or unsubstituted carbocyclic or heterocyclic monovalent group, or R^2 and R^3, or R^2 and R^1 may form together and with the atoms linking them, a substituted or unsubstituted ring;

R^4 is selected from the group consisting of a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted carbocyclic or heterocyclic monovalent group, hydroxyl, mercapto, azido, nitro, halo, cyano, unsubstituted or substituted acyl, amino, cyanato, thiocyanato, $-SF_5$, $-OR^a$, $-SR^a$, and $-Si(R^a)_3$;

m = 0, 1, 2 or 3;

the optional R^5 group or the optional R^5 groups, which may be mutually identical or different, have the same definition as that given above for R^4;

R^6 is an unsubstituted or substituted carbocyclic or heterocyclic group; and

A is selected from the group consisting of a direct bond, -O-, -S(O)–, $-NR^9$-, $-CR^7=CR^7$-, $-C\equiv C$-, $-A^1$-, $-A^1-A^1$, $-O-(A^1)_k-O$-, $-O-(A^1)_k$-, $-A^3$-, $-A^4$-, $-A^1O$-, $-A^1S(O)$–, $-A^2$-, OA^2-, $-NR^9A^2$-,

$-OA^2-A^1-$, $-OA^2-C(R^7)=C(R^8)-$, $-S(O)_nA^1-$, $-A^1-A^4-$, $-A^1-A^4-C(R^8)=$ N-N=CR^8-,

$-A^1-A^4-C(R^8)=N-X^2-X^3-$, $-A^1-A^4-A^3-$, $-A^1-A^4-N(R^9)-$, $-A^1-A^4-X-CH_2-$, $-A^1-A^4-A^1-$, $-A^1-A^4-CH_2X-$,

$-A^1-A^4-C(R_8)=N-X^2-X^3-X^1-$, $-A^1-X-C(R^8)=-$, $-A^1-X-C(R^8)=N-N=CR^8-$, $-A^1-X-C(R^8)=N-N(R^9)-$,

$-A^1-X-A-X^1-$, $-A^1-O-A^3-$, $-A^1-O-C(R^7)=C(R^8)-$, $-A^1-O-N(R^9)-A^2-$ $(R^9)-$, $-A^1-O-N(R^9)-A^2-$,

$-A^1-N(R^9)-A^2-N(R^9)-$, $-A^1-N(R^9)-A^2-$, $-A^1-N(R^9)-N=C(R^8)-$, $-A^3-A^1-$, $-A^4-A^3-$, $-A^2-NR^9-$,

$-A^1-A^2-X^1-$, $-A^1-A^1-A^2-X^1-$, $-O-A^2-N(R^9)-A^2-$, $-CR^7=CR^7-A^2-X^1-$, $-C\equiv C-A^2-X^1-$,

$-N=C(R^8)-A^2-X^1-$, $-C(R^8)=N-N=C(R^8)-$, $-C(R^8)=N-N(R^9)-$, $-(CH_2)_2-O-N=C(R^8)-$ and

$-X-A^2-N(R^9)-$

wherein

n = 0, 1 or 2,

k = 1 to 9,

$A^1 = -CHR^7-$,

$A^2 = -C(=X)-$,

$A^3 = -C(R^8)=N-O-$,

$A^4 = -O-N=C(R^8)-$,

X = O or S,

X^1 = O, S, NR^9 or a direct bond,

X^2 = O, NR^9 or a direct bond,

X^3 = hydrogen, $-C(=O)-$, $-SO_2-$ or a direct bond,

each R^7 is independently selected from the group consisting of unsubstituted or substituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted phenyl, hydrogen, halogen,cyano, and acyl;

each R^8 is independently selected from the group consisting of alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylthio, a substituted or unsubstituted carbocyclic or heterocyclic monovalent group, and hydrogen;

each R^9 is independently selected from the group consisting of unsubstituted or substituted alkyl, a substituted or unsubstituted monovalent carbocyclic or heterocyclic group, and acyl; or two R^9 groups may form together, and with the atoms linking them, a 5-7-membered ring;

the group represented on the right side of the bond A is linked to R^6;

or -A-R^6 and R^5 form together with the benzene ring M, a system of unsubstituted or substituted condensed rings;

and optical and/or geometric isomers, tautomers and salts of (I) with an acid or a base that are pharmaceutically acceptable;

and mixtures thereof.

17. (New) The method of claim 5 wherein compound (I) is selected from the group consisting of N-ethyl-N-methyl-N'-[4-(4-chloro-3-trifluoromethylphenoxy)-2,5-

dimethylphenyl]imidoformamide and N-ethyl-N-methyl-N'-[4-(4-cyano-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide and compound (II) is selected from the group consisting of fluconazole and itraconazole.

18. (New) The method of claim 7 wherein compound (I) is selected from the group consisting of N-ethyl-N-methyl-N'-[4-(4-chloro-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide and N-ethyl-N-methyl-N'-[4-(4-cyano-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide and compound (II) is selected from the group consisting of fluconazole and itraconazole.

19. (New) The method of claim 9 wherein compound (I) is selected from the group consisting of N-ethyl-N-methyl-N'-[4-(4-chloro-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide and N-ethyl-N-methyl-N'-[4-(4-cyano-3-trifluoromethylphenoxy)-2,5-dimethylphenyl]imidoformamide and compound (II) is selected from the group consisting of fluconazole and itraconazole.